SNO 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Immunotherapy and immunobiology at SNO 2026

Nov 12–15, 2026 Philadelphia, PA ~3k attendees Website

64 organizations at SNO 2026 present work in immunobiology, immunotherapy and cell therapies, led by hospitals and cancer centers. Between them they bring 879 presentations to the program. Most represented: Mayo Clinic, University of California, San Francisco (UCSF) and MD Anderson Cancer Center. As of Nov 12, 2026.

All 419 organizations at SNO 2026 →

Format
Top represented
Showing 1–1 of 64 organizations
OrganizationSNO 2026 Attendance
Mayo Clinic
Rochester, MN
Hospitals & cancer centers
A nonprofit academic medical center with cancer programs and neuro-oncology care and research across its campuses.
Session
Thu Nov 12
8:30–8:40am
Session
Thu Nov 12
8:40–9:55am
2026 SNO Education Day - Opening Session
Exhibit Hall C, Second Floor, Convention Center
Immunology
Session
Thu Nov 12
10:10–11:45am
Session II: Biomarkers - How to Measure
Terrace Ballroom IV Convention Center
Biomarkers
Session
Thu Nov 12
12:35–2:10pm
Session III: Targeting Therapy - Making it Happen
Exhibit Hall C, Second Floor, Convention Center
Therapeutics
Talk
Thu Nov 12
12:35–2:10pm
Talk
Thu Nov 12
2–3:30pm
Session
Thu Nov 12
4:25–4:30pm
2026 SNO Education Day - Closing Remarks
Exhibit Hall C, Second Floor, Convention Center
Session
Thu Nov 12
4:30–5:35pm
Session
Fri Nov 13
8:30–10am
Plenary I
Exhibit Hall C, Second Floor, Convention Center
Plenary
Fri Nov 13
8:30–10am
Part of Plenary I
2026 Award for Excellence in Neuro-Oncology Education
Exhibit Hall C, Second Floor, Convention Center
Session
Fri Nov 13
10:15–11:15am
Clinical Trials Oral Abstracts Session I
118 ABC, First Floor, Convention Center
Trials
Session
Fri Nov 13
10:15–11:15am
Talk
Fri Nov 13
10:22–10:29am
DNA copy number clustering identifies risk-associated profiles in IDH-mutant, 1p/19q-codeleted oligodendrogliomas
120 ABC, First Floor, Convention Center · Abstract BIOM-27
Biomarkers · Pathology
Talk
Fri Nov 13
10:54–10:59am
TP53 status predicts response to Lomustine therapy in IDH-WT Glioblastoma.
120 ABC, First Floor, Convention Center · Abstract BIOM-24
Biomarkers · Pathology
Talk
Fri Nov 13
10:59–11:04am
Multi-omic profiling of IDH-mutant diffuse gliomas with non-canonical 1p/19q co-deletions
120 ABC, First Floor, Convention Center · Abstract PATH-50
Pathology
Session
Fri Nov 13
11:30am–12:30pm
Rapid Orals Session VI A
Exhibit Hall D & E, Second Floor, Convention Center
Talk
Fri Nov 13
11:33–11:36am
Agonistic TREM2 therapy drives tumor-associated microglial engagement and durable anti-tumor immunity in glioblastoma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract IMMU-49
Immunology
Session
Fri Nov 13
12:45–2:15pm
Plenary II
Exhibit Hall C, Second Floor, Convention Center
Session
Fri Nov 13
2:30–3:30pm
CNS Rare Tumor Oral Abstracts Session I
119 AB, First Floor, Convention Center
Rare tumors
Talk
Fri Nov 13
3:14–3:19pm
Session
Fri Nov 13
3:45–4:45pm
Basic Science Oral Abstracts Session I
118 ABC, First Floor, Convention Center
Tumor biology
Session
Fri Nov 13
3:45–4:45pm
Talk
Fri Nov 13
3:45–4:45pm
Session
Fri Nov 13
5–6pm
Neurologic Complications of Antineoplastic Therapies
Terrace Ballroom I Convention Center
Survivorship
Poster
Fri Nov 13
7:30–9:30pm
Bevacizumab and Tocilizumab for Recurrent Adamantinomatous Craniopharyngioma: A Case Series
Exhibit Hall D & E, Second Floor, Convention Center · Abstract BIOM-47
Biomarkers
Poster
Fri Nov 13
7:30–9:30pm
Characterization of IL6R and VEGFR Expression in Papillary Craniopharyngioma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract BIOM-56
Biomarkers
Poster
Fri Nov 13
7:30–9:30pm
Deconvolution of plasma and blood signatures from the glioma CSF proteome for biomarker discovery
Exhibit Hall D & E, Second Floor, Convention Center · Abstract BIOM-70
Biomarkers
Poster
Fri Nov 13
7:30–9:30pm
Effect of Pembrolizumab Administration on Survival in IDH-Wildtype Glioblastoma Multiforme Patients
Exhibit Hall D & E, Second Floor, Convention Center · Abstract CNSC-82
Neuroscience
Poster
Fri Nov 13
7:30–9:30pm
Poster
Fri Nov 13
7:30–9:30pm
Poster
Fri Nov 13
7:30–9:30pm
Enhancing antibody delivery to the brain using antiviral immune response
Exhibit Hall D & E, Second Floor, Convention Center · Abstract DDEL-06
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
Targeted therapy outcomes among patients with BRAF-pathway altered glioma – a single institution experience
Exhibit Hall D & E, Second Floor, Convention Center · Abstract DDEL-14
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
Potentiating the Effect of MGMT-sensitive DNA Interstrand Crosslinking Agents by Targeting HDAC Function in IDH1/2 Mutant Gliomas
Exhibit Hall D & E, Second Floor, Convention Center · Abstract DNAR-15
Tumor biology
Poster
Fri Nov 13
7:30–9:30pm
Progression-free survival after first progression in CDKN2A/B homozygous-deleted grade 4 IDH-mutant astrocytoma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract EPID-20
Health equity
Poster
Fri Nov 13
7:30–9:30pm
A new framework for engaging patients and the public in basic cancer research
Exhibit Hall D & E, Second Floor, Convention Center · Abstract EXTH-04
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
An In Vivo Approach to Identify Determinants of Response to MDM2 Inhibitor Therapy in Glioblastoma Patient Derived Xenografts
Exhibit Hall D & E, Second Floor, Convention Center · Abstract EXTH-52
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
Testosterone Replacement Therapy and Tumor Survival: Effects Across Brain Cancers
Exhibit Hall D & E, Second Floor, Convention Center · Abstract EXTH-92
Therapeutics
Poster
Fri Nov 13
7:30–9:30pm
Primary dural follicular lymphoma: a case presentation of an exceedingly rare and indolent meningioma mimic
Exhibit Hall D & E, Second Floor, Convention Center · Abstract IMG-72
Neuroimaging
Poster
Fri Nov 13
7:30–9:30pm
Poster
Fri Nov 13
7:30–9:30pm
Risk-Stratified short-course bevacizumab for radiation necrosis in brain metastasis patients with elevated hemorrhagic risk
Exhibit Hall D & E, Second Floor, Convention Center · Abstract INNV-26
Survivorship
Poster
Fri Nov 13
7:30–9:30pm
From mood to malignancy: investigating fluoxetine’s roles in glioblastoma outcomes
Exhibit Hall D & E, Second Floor, Convention Center · Abstract INNV-37
Survivorship
Poster
Fri Nov 13
7:30–9:30pm
Spectrum ischemic stroke in patients with gynecologic malignancy: a population-based study of etiology, risk factors, and outcomes
Exhibit Hall D & E, Second Floor, Convention Center · Abstract NCMP-04
Survivorship
Poster
Fri Nov 13
7:30–9:30pm
Poster
Fri Nov 13
7:30–9:30pm
Surgical outcomes of intra-axial frontal operculum tumors
Exhibit Hall D & E, Second Floor, Convention Center · Abstract NCOG-14
Survivorship
Poster
Fri Nov 13
7:30–9:30pm
Safety of frameless stereotactic brain tumor biopsy in a large contemporary series.
Exhibit Hall D & E, Second Floor, Convention Center · Abstract NCOG-54
Survivorship
Poster
Fri Nov 13
7:30–9:30pm
Long‑Term Survival in MGMT Promoter-Unmethylated IDH‑Wildtype Glioblastoma: Clinical and Molecular Features of ≥3‑Year Survivors
Exhibit Hall D & E, Second Floor, Convention Center · Abstract NCOG-59
Survivorship
Poster
Fri Nov 13
7:30–9:30pm
Molecular Grade predicts progression-free-survival after proton beam radiotherapy in intracranial meningiomas
Exhibit Hall D & E, Second Floor, Convention Center · Abstract RADT-34
Radiation
Poster
Fri Nov 13
7:30–9:30pm
Clinical Performance of Two Brain Metastasis Prognostic Systems for 90-Day Mortality After Stereotactic Radiosurgery for Brain Metastases
Exhibit Hall D & E, Second Floor, Convention Center · Abstract RADT-45
Radiation
Poster
Fri Nov 13
7:30–9:30pm
Turnaround time of EHR integrated patient-generated escalations in a decentralized neuro-oncology trial (GHoST)
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TIP-23
Trials
Poster
Fri Nov 13
7:30–9:30pm
The impact of resection and location on the glioma cerebrospinal fluid metabolome
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMET-25
Tumor biology
Poster
Fri Nov 13
7:30–9:30pm
Direct in vivo mapping reveals hypoxia as a spatially distributed driver of malignant cell plasticity in glioblastoma
Exhibit Hall D & E, Second Floor, Convention Center · Abstract TMIC-54
Tumor biology
Session
Sat Nov 14
8:30–10am
Plenary III
Exhibit Hall C, Second Floor, Convention Center
Plenary
Sat Nov 14
8:30–10am
Part of Plenary III
Presidential Address
Exhibit Hall C, Second Floor, Convention Center
Session
Sat Nov 14
10:15–11:15am
ASNO - SNO Joint Session: Digital Pathology and AI Advances in Meningiomas
Terrace Ballroom I Convention Center
Pathology
Session
Sat Nov 14
10:15–11:15am
Why Neuro‑Oncology Trials Fail - and How to Design Them to Succeed
Terrace Ballroom II & III Convention Center
Trials
Talk
Sat Nov 14
10:15–11:15am
Talk
Sat Nov 14
10:15–11:15am
Talk
Sat Nov 14
11:42–11:45am
A new 3F’s Framework for guiding early, developmentally attuned conversations with AYA cancer patients
Exhibit Hall D & E, Second Floor, Convention Center · Abstract QOL-02
Survivorship
Talk
Sat Nov 14
11:45–11:48am
SPAK and OSR1 kinases drive mesenchymal glioblastoma progression and represent a therapeutic vulnerability
Exhibit Hall D & E, Second Floor, Convention Center · Abstract ANGI-06
Tumor biology
Talk
Sat Nov 14
11:54–11:57am
Counterproductive Effects of Mutant IDH1/2 Enzyme Inhibition in a Subset of High-grade IDH1/2 Mutant Gliomas
Exhibit Hall D & E, Second Floor, Convention Center · Abstract DDDR-30
Therapeutics
Talk
Sat Nov 14
12:21–12:24pm
Session
Sat Nov 14
12:45–2:15pm
Plenary IV
Exhibit Hall C, Second Floor, Convention Center
Talk
Sat Nov 14
3:09–3:14pm
Talk
Sat Nov 14
4:24–4:29pm
Session
Sat Nov 14
5–6pm
CNS Rare Tumor Oral Abstracts Session II
119 AB, First Floor, Convention Center
Rare tumors
Session
Sun Nov 15
8:30–9:30am
Primary and Secondary CNS Lymphoma
Terrace Ballroom IV Convention Center
Lymphoma
Talk
Sun Nov 15
8:30–9:30am
Talk
Sun Nov 15
9:45–10:45am
Session
Sun Nov 15
11am–12pm
Update on Therapeutic Strategies for Chordoma
Terrace Ballroom I Convention Center
Rare tumors
Talk
Sun Nov 15
11am–12pm
Update on Therapeutic Strategies for Chordoma
Terrace Ballroom I Convention Center
Rare tumors
Talk
Sun Nov 15
11:21–11:28am
Plasma extracellular vesicles as a source of direct tumor antigens in glioblastoma
118 ABC, First Floor, Convention Center · Abstract BIOM-11
Biomarkers · Tumor biology

Explore the full SNO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Philadelphia. Leave your work email and we’ll be in touch.

Privacy

Download the full SNO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in immunobiology, immunotherapy and cell therapies

Tell us what you sell and we’ll find the people at organizations working on immunobiology, immunotherapy and cell therapies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse SNO 2026 by

Not affiliated with or endorsed by the Society for Neuro-Oncology. Submit a correction